Genmab shares fell on Monday after the company said it would end the development of blood-cancer treatment HexaBody-CD38 because Johnson & Johnson won't exercise its option to license it.

Genmab A/S(Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody ...

Copenhagen-based biotech firm Genmab A/S disclosed today that Johnson & Johnson will not advance the HexaBody-CD38 program, as detailed in a recent SEC filing. The announcement was made in a Form ...